The DOI matches its Crossref record; 182 of the 182 references it cites were found in a registry or an index.
Phage display-derived human antibodies in clinical development and therapy
Open accessAbstract
Over the last 3 decades, monoclonal antibodies have become the most important class of therapeutic biologicals on the market. Development of therapeutic antibodies was accelerated by recombinant DNA technologies, which allowed the humanization of murine monoclonal antibodies to make them more similar to those of the human body and suitable for a broad range of chronic diseases like cancer and autoimmune diseases. In the early 1990s in vitro antibody selection technologies were developed that enabled the discovery of "fully" human antibodies with potentially superior clinical efficacy and lowest immunogenicity. Antibody phage display is the first and most widely used of the in vitro selection technologies. It has proven to be a robust, versatile platform technology for the discovery of human antibodies and a powerful engineering tool to improve antibody properties. As of the beginning of 2016, 6 human antibodies discovered or further developed by phage display were approved for therapy. In 2002, adalimumab (Humira®) became the first phage display-derived antibody granted a marketing approval. Humira® was also the first approved human antibody, and it is currently the best-selling antibody drug on the market. Numerous phage display-derived antibodies are currently under advanced clinical investigation, and, despite the availability of other technologies such as human antibody-producing transgenic mice, phage display has not lost its importance for the discovery and engineering of therapeutic antibodies. Here, we provide a comprehensive overview about phage display-derived antibodies that are approved for therapy or in clinical development. A selection of these antibodies is described in more detail to demonstrate different aspects of the phage display technology and its development over the last 25 years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Smith, G. P. (1985) · Science · doi:10.1126/science.4001944 · Cited by 4,143
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Folkman, J., & Klagsbrun, M. (1987) · Science · doi:10.1126/science.2432664 · Cited by 3,491
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Rapid generation of functional human IgG antibodies derived from Fab-on-phage display libraries
Jostock, T., Vanhove, M., Brepoels, E., van Gool, R., Daukandt, M., Wehnert, A., van Hegelsom, R., Dransfield, D., Sexton, D., Devlin, M., et al. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.03.014 · Cited by 2,572
Phage antibodies: filamentous phage displaying antibody variable domains
McCafferty, J., Griffiths, A. D., Winter, G., & Chiswell, D. J. (1990) · Nature · doi:10.1038/348552a0 · Cited by 2,423
Fuchs, C. S., Tomasek, J., Yong, C. J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. V., Aprile, G., Ferry, D. R., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61719-5 · Cited by 2,188
Navarra, S. V., Guzmán, R. M., Gallacher, A. E., Hall, S., Levy, R. A., Jimenez, R. E., Li, E. K.-M., Thomas, M., Kim, H.-Y., León, M. G., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61354-2 · Cited by 2,074
The fms -Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor
de Vries, C., Escobedo, J. A., Ueno, H., Houck, K., Ferrara, N., & Williams, L. T. (1992) · Science · doi:10.1126/science.1312256 · Cited by 2,016
Weinblatt, M. E., Keystone, E. C., Furst, D. E., Moreland, L. W., Weisman, M. H., Birbara, C. A., Teoh, L. A., Fischkoff, S. A., & Chartash, E. K. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10697 · Cited by 1,757
Maloney, D. G., Grillo-López, A. J., White, C. A., Bodkin, D., Schilder, R. J., Neidhart, J. A., Janakiraman, N., Foon, K. A., Liles, T.-M., Dallaire, B. K., et al. (1997) · Blood · doi:10.1182/blood.v90.6.2188 · Cited by 1,733
VEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691 · cited 1×
“VEGF-trap) fused to human IgG1 Fc discovered by Regeneron and named aflibercept (Eylea , approved for AMD in 2011; co-development with Bayer) or ziv-aflibercept (Zaltrap , approved in 2012 for colorectal cancer; co-development with Sanofi).(184) Another strategy was the inhibition of the VEGF receptors.”
Presta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., KRUMMEN, L. A., Winkler, M., & Ferrara, N. (1997) · PubMed · Cited by 1,608
Making antibodies by phage display technology
Winter, G., Griffiths, A. D., Hawkins, R. E., & Hoogenboom, H. R. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.002245 · Cited by 1,573
Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor
Terman, B. I., Dougher-Vermazen, M., Carrion, M. E., Dimitrov, D., Armellino, D. C., Gospodarowicz, D., & Böhlen, P. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(92)90483-2 · Cited by 1,519
Single-Chain Antigen-Binding Proteins
Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S.-M., Lee, T., Pope, S. H., Riordan, G. S., & Whitlow, M. (1988) · Science · doi:10.1126/science.3140379 · Cited by 1,502
BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth
Schneider, P., MacKay, F., Steiner, V., Hofmann, K., Bodmer, J.-L., Holler, N., Ambrose, C., Lawton, P., Bixler, S., Acha-Orbea, H., et al. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.11.1747 · Cited by 1,333
Colony-stimulating factors in inflammation and autoimmunity
Hamilton, J. A. (2008) · Nature reviews. Immunology · doi:10.1038/nri2356 · Cited by 1,305 · cited 1×
“The proinflammatory cytokine GM-CSF is produced by a variety of cells including activated T and B cells, monocytes/ macrophages, endothelial cells, and fibroblasts and it stimulates myeloid differentiation of haematopoietic stem cells, proliferation and activation of macrophages, monocytes, neutrophils, eosinophils, d…”
BackgroundThe therapeutic monoclonal antibody market
Ecker, D. M., Jones, S. D., & Levine, H. L. (2015) · mAbs · doi:10.4161/19420862.2015.989042 · Cited by 1,286
The Tumor Necrosis Factor Ligand and Receptor Families
Bazzoni, F., & Beutler, B. (1996) · New England Journal of Medicine · doi:10.1056/nejm199606273342607 · Cited by 1,225
Making antibody fragments using phage display libraries
Clackson, T., Hoogenboom, H. R., Griffiths, A. D., & Winter, G. (1991) · Nature · doi:10.1038/352624a0 · Cited by 1,203
Assembly of combinatorial antibody libraries on phage surfaces: the gene III site.
Barbas, C. F., Kang, A. S., Lerner, R. A., & Benkovic, S. J. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.18.7978 · Cited by 1,183
BLyS: Member of the Tumor Necrosis Factor Family and B Lymphocyte Stimulator
Moore, P. A., Belvedere, O., Orr, A., Pieri, K., LaFleur, D. W., Feng, P., Soppet, D., Charters, M., Gentz, R., Parmelee, D., et al. (1999) · Science · doi:10.1126/science.285.5425.260 · Cited by 1,144
BRENNAN, F. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90430-3 · Cited by 1,129
Vaughan, T. J., Williams, A. J., Pritchard, K., Osbourn, J. K., Pope, A. R., Earnshaw, J. C., McCafferty, J., Hodits, R. A., Wilton, J., & Johnson, K. S. (1996) · Nature Biotechnology · doi:10.1038/nbt0396-309 · Cited by 1,027
Anthrax as a Biological Weapon, 2002: Updated Recommendations for Management
Inglesby, T. V., O'Toole, T., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Friedlander, A. M., Gerberding, J., Hauer, J., Hughes, J., et al. (2002) · JAMA · doi:10.1001/jama.287.17.2236 · Cited by 1,027
Development trends for human monoclonal antibody therapeutics
Nelson, A. L., Dhimolea, E., & Reichert, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3229 · Cited by 1,026
Holmes, K., Roberts, O. L., Thomas, A. M., & Cross, M. J. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.05.013 · Cited by 1,020
Assembly of a Functional Immunoglobulin F v Fragment in Escherichia coli
Skerra, A., & Plückthun, A. (1988) · Science · doi:10.1126/science.3285470 · Cited by 978
Isolation of high affinity human antibodies directly from large synthetic repertoires.
Griffiths, A. D., Williams, S. C., Hartley, O., Tomlinson, I. M., Waterhouse, P., Crosby, W. L., Kontermann, R. E., Jones, P. T., Low, N. M., & Allison, T. J. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06626.x · Cited by 962
Shibuya, M., Yamaguchi, S., Yamane, A., Ikeda, T., Tojo, A., Matsushime, H., & Sato, M. (1990) · PubMed · Cited by 960
The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy
Scaltriti, M., & Baselga, J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1554 · Cited by 913
Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals
Scheid, J. F., Mouquet, H., Feldhahn, N., Seaman, M. S., Velinzon, K., Pietzsch, J., Ott, R. G., Anthony, R. M., Zebroski, H., Hurley, A., et al. (2009) · Nature · doi:10.1038/nature07930 · Cited by 867
Antibody-selectable filamentous fd phage vectors: affinity purification of target genes
Parmley, S. F., & Smith, G. P. (1988) · Gene · doi:10.1016/0378-1119(88)90495-7 · Cited by 867
Interleukin-2–Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal Transplantation
Vincenti, F., Kirkman, R., Light, S., Bumgardner, G., Pescovitz, M., Halloran, P., Neylan, J., Wilkinson, A., Ekberg, H., Gaston, R., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801153380304 · Cited by 864
Cheema, G. S., Roschke, V., Hilbert, D. M., & Stohl, W. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200106)44:6<1313::aid-art223>3.0.co;2-s · Cited by 802
Lisnevskaia, L., Murphy, G., & Isenberg, D. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60128-8 · Cited by 752
Cutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus Erythematosus
Zhang, J., Roschke, V., Baker, K. P., Wang, Z., Alarcón, G. S., Fessler, B. J., Bastian, H., Kimberly, R. P., & Zhou, T. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.6 · Cited by 734
Knappik, A., Ge, L., Honegger, A., Pack, P., Fischer, M., Wellnhofer, G., Hoess, A., Wölle, J., Plückthun, A., & Virnekäs, B. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3444 · Cited by 728
Burton, D. R., Barbas, C. F., Persson, M. A., Koenig, S., Chanock, R. M., & Lerner, R. A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.22.10134 · Cited by 663
Identification of a new endothelial cell growth factor receptor tyrosine kinase.
Terman, B. I., Carrion, M. E., Kovacs, E., Rasmussen, B. A., Eddy, R. L., & Shows, T. B. (1991) · Oncogene · Cited by 641
Immunogenicity of engineered antibodies
Hwang, W. Y. K., & Foote, J. (2005) · Methods · doi:10.1016/j.ymeth.2005.01.001 · Cited by 630
Antibody arrays for high-throughput screening of antibody–antigen interactions
de Wildt, R. M. T., Mundy, C. R., Gorick, B. D., & Tomlinson, I. M. (2000) · Nature Biotechnology · doi:10.1038/79494 · Cited by 624
van de Putte, L. B. A., Atkins, C., Malaise, M., Sany, J., Russell, A. S., van Riel, P. L. C. M., Settas, L., Bijlsma, J. W., Todesco, S., Dougados, M., et al. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.013052 · Cited by 617
Vascular endothelial growth factor (VEGF) signaling in tumor progression
Roskoski, R. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.01.006 · Cited by 599
Burmester, G. R., Panaccione, R., Gordon, K. B., McIlraith, M. J., & Lacerda, A. P. M. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-201244 · Cited by 591
Wallace, D. J., Stohl, W., Furie, R. A., Lisse, J. R., McKay, J. D., Merrill, J. T., Petri, M. A., Ginzler, E. M., Chatham, W. W., McCune, W. J., et al. (2009) · Arthritis Care & Research · doi:10.1002/art.24699 · Cited by 585
Colman, R. W., & Schmaier, A. H. (1997) · Blood · doi:10.1182/blood.v90.10.3819 · Cited by 581
Single domain camel antibodies: current status
Muyldermans, S. (2001) · Reviews in Molecular Biotechnology · doi:10.1016/s1389-0352(01)00021-6 · Cited by 552
Spratlin, J. L., Cohen, R. B., Eadens, M., Gore, L., Camidge, D. R., Diab, S., Leong, S., O'Bryant, C., Chow, L. Q. M., Serkova, N. J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7537 · Cited by 549
Beyond natural antibodies: the power of in vitro display technologies
Bradbury, A. R. M., Sidhu, S., Dübel, S., & McCafferty, J. (2011) · Nature Biotechnology · doi:10.1038/nbt.1791 · Cited by 545
Vascular Endothelial Growth Factor: Molecular and Biological Aspects
Ferrara, N. (1999) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-59953-8_1 · Cited by 533
Camelid immunoglobulins and nanobody technology
Muyldermans, S., Baral, T. N., Retamozzo, V. C., De Baetselier, P., De Genst, E., Kinne, J., Leonhardt, H., Magez, S., Nguyen, V. K., Revets, H., et al. (2009) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2008.10.299 · Cited by 533
de Haard, H. J., van Neer, N., Reurs, A., Hufton, S. E., Roovers, R. C., Henderikx, P., de Bruı̈ne, A. P., Arends, J.-W., & Hoogenboom, H. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.26.18218 · Cited by 533
Rusch, V. W., Baselga, J. M., Cordon‐Cardo, C., Orazem, J. P., Zaman, M., Hoda, S. A., McIntosh, J., Kurie, J. M., & Dmitrovsky, E. (1993) · PubMed · Cited by 482
Thatcher, N., Hirsch, F. R., Luft, A. V., Szczesna, A., Ciuleanu, T. E., Dediu, M., Ramlau, R., Galiulin, R. K., Bálint, B., Losonczy, G., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00021-2 · Cited by 479
Granulocyte Macrophage Colony-Stimulating Factor
McQualter, J. L., Darwiche, R., Ewing, C., Onuki, M., Kay, T. W., Hamilton, J. A., Reid, H. H., & Bernard, C. C. A. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.7.873 · Cited by 477
Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2
Oliner, J., Min, H., Leal, J., Yu, D., Rao, S., You, E., Tang, X., Kim, H., Meyer, S., Han, S. J., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.030 · Cited by 471
Chen, Y., Wiesmann, C., Fuh, G., Li, B., Christinger, H. W., McKay, P., de Vos, A. M., & Lowman, H. B. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3192 · Cited by 448
Glanville, J., Zhai, W., Berka, J., Telman, D., Huerta, G., Mehta, G. R., Ni, I., Mei, L., Sundar, P. D., Day, G. M. R., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909775106 · Cited by 440
Design and Use of a Phage Display Library
Pini, A., Viti, F., Santucci, A., Carnemolla, B., Zardi, L., Neri, P., & Neri, D. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.34.21769 · Cited by 422
Rusch, V. W., Klimstra, D. S., Venkatraman, E. S., Pisters, P. W. T., Langenfeld, J. E., & Dmitrovsky, E. (1997) · PubMed · Cited by 401
Schiff, M. H., Burmester, G. R., Kent, J. D., Pangan, A. L., Kupper, H., Fitzpatrick, S. B., & Donovan, C. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.043166 · Cited by 390
Panacek, E. A., Marshall, J. C., Albertson, T. E., Johnson, D. H., Johnson, S., MacArthur, R. D., Miller, M., Barchuk, W. T., Fischkoff, S., Kaul, M., et al. (2004) · Critical Care Medicine · doi:10.1097/01.ccm.0000145229.59014.6c · Cited by 387
Liang, W.-C., Wu, X., Peale, F. V., Lee, C. V., Meng, Y. G., Gutierrez, J., Fu, L., Malik, A. K., Gerber, H.-P., Ferrara, N., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508199200 · Cited by 346
Domain antibodies: proteins for therapy
Holt, L. J., Herring, C., Jespers, L. S., Woolven, B. P., & Tomlinson, I. M. (2003) · Trends in Biotechnology · doi:10.1016/j.tibtech.2003.08.007 · Cited by 345
Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries
Söderlind, E., Strandberg, L., Jirholt, P., Kobayashi, N., Alexeiva, V., Åberg, A.-M., Nilsson, A., Jansson, B., Ohlin, M., Wingren, C., et al. (2000) · Nature Biotechnology · doi:10.1038/78458 · Cited by 337
Pajusola, K., Aprelikova, O. N., Korhonen, J., Kaipainen, A., Pertovaara, L., Alitalo, R., & Alitalo, K. K. (1992) · PubMed · Cited by 336
Kaymakcalan, Z., Sakorafas, P., Bose, S., Scesney, S., Xiong, L., Hanzatian, D. K., Salfeld, J., & Sasso, E. H. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.01.002 · Cited by 317
Bielekova, B., Richert, N., Howard, T., Blevins, G., Markovic-Plese, S., McCartin, J., Würfel, J., Ohayon, J., Waldmann, T. A., McFarland, H. F., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402653101 · Cited by 315
Hoet, R. M., Cohen, E. H., Kent, R. B., Rookey, K., Schoonbroodt, S., Hogan, S., Rem, L., Frans, N., Daukandt, M., Pieters, H., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1067 · Cited by 315
Tolcher, A. W., Mita, M., Meropol, N. J., von Mehren, M., Patnaik, A., Padavic, K., Hill, M., Mays, T., McCoy, T., Fox, N. L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8898 · Cited by 314
Angiogenesis: a Dynamic Balance of Stimulators and Inhibitors
Iruela-Arispe, L. M., & Dvorak, H. F. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1657610 · Cited by 311
Pukac, L., Kanakaraj, P., Humphreys, R., Alderson, R., Bloom, M., Sung, C., Riccobene, T., Johnson, R., Fiscella, M., Mahoney, A., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602487 · Cited by 306 · cited 3×
“It induces cell death in multiple tumor cell lines in vitro and in vivo, which can be enhanced by combination with chemotherapeutic agents like camptothecin, cisplatin, carboplatin, or 5-fluorouracil.(126) Mapatumumab demonstrated safety and tolerability in cancer patients with advanced solid tumors or non-Hodgkin’s l…”
BackgroundMethodInfluentialA surface expression vector for antibody screening
Breitling, F., Dübel, S., Seehaus, T., Klewinghaus, I., & Little, M. (1991) · Gene · doi:10.1016/0378-1119(91)90244-6 · Cited by 305
The Role of IL-23/IL-17 Axis in Lupus Nephritis
Zhang, Z., Kyttaris, V. C., & Tsokos, G. C. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900385 · Cited by 303
Weisman, M. H., Moreland, L. W., Furst, D. E., Weinblatt, M. E., Keystone, E. C., Paulus, H. E., Teoh, L. S., Velagapudi, R. B., Noertersheuser, P. A., Granneman, G. R., et al. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80164-9 · Cited by 303
A helper phage to improve single-chain antibody presentation in phage display
Rondot, S., Koch, J., Breitling, F., & Dübel, S. (2001) · Nature Biotechnology · doi:10.1038/83567 · Cited by 300
The ErbB Receptors and their Ligands in Cancer: An Overview
Normanno, N., Bianco, C., Strizzi, L., Mancino, M., Maiello, M., Luca, A., Caponigro, F., & Salomon, D. (2005) · Current Drug Targets · doi:10.2174/1389450053765879 · Cited by 275
Comparison of Age-related Macular Degeneration Treatments Trials Research, G. (2011) · doi:10.1056/nejmicm1005605 · Cited by 273
High-avidity human IgGκ monoclonal antibodies from a novel strain of minilocus transgenic mice
Fishwild, D. M., O'Donnell, S. L., Bengoechea, T., Hudson, D. V., Harding, F., Bernhard, S. L., Jones, D., Kay, R. M., Higgins, K. M., Schramm, S. R., et al. (1996) · Nature Biotechnology · doi:10.1038/nbt0796-845 · Cited by 266
Muller, Y. A., Chen, Y., Christinger, H. W., Li, B., Cunningham, B. C., Lowman, H. B., & de Vos, A. M. (1998) · Structure · doi:10.1016/s0969-2126(98)00116-6 · Cited by 264
Rothe, C., Urlinger, S., Löhning, C., Prassler, J., Stark, Y., Jäger, U., Hubner, B., Bardroff, M., Pradel, I., Boss, M., et al. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.12.018 · Cited by 247
Engineering of therapeutic antibodies to minimize immunogenicity and optimize function
Presta, L. G. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.01.026 · Cited by 246
Soria, J.-C., Márk, Z., Zatloukal, P., Szima, B., Albert, I., Juhász, E., Pujol, J.-L., Kozielski, J., Baker, N., Smethurst, D., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.2623 · Cited by 246
Application of phage display to high throughput antibody generation and characterization
Schofield, D. J., Pope, A. R., Clementel, V., Buckell, J., Chapple, S. D., Clarke, K. F., Conquer, J. S., Crofts, A. M., Crowther, S. R., Dyson, M. R., et al. (2007) · Genome Biology · doi:10.1186/gb-2007-8-11-r254 · Cited by 236
Virnekas, B., Ge, L., Plu€kthun, A., Schneider, K. C., Wellnhofer, G., & Moroney, S. E. (1994) · Nucleic Acids Research · doi:10.1093/nar/22.25.5600 · Cited by 234
Anthrax lethal and edema toxins in anthrax pathogenesis
Liu, S., Moayeri, M., & Leppla, S. H. (2014) · Trends in Microbiology · doi:10.1016/j.tim.2014.02.012 · Cited by 217
Tiller, T., Schuster, I., Deppe, D., Siegers, K., Strohner, R., Herrmann, T., Berenguer, M., Poujol, D., Stehle, J., Stark, Y., et al. (2013) · mAbs · doi:10.4161/mabs.24218 · Cited by 205
Jäger, V., Büssow, K., Wagner, A., Weber, S., Hust, M., Frenzel, A., & Schirrmann, T. (2013) · BMC Biotechnology · doi:10.1186/1472-6750-13-52 · Cited by 200
Self-citationHotte, S. J., Hirte, H. W., Chen, E. X., Siu, L. L., Le, L. H., Corey, A., Iacobucci, A., MacLean, M., Lo, L., Fox, N. L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1416 · Cited by 190
Carrieri, P. B., Provitera, V., Rosa, T. D., Tartaglia, G., Gorga, F., & Perrella, O. (1998) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923979809034820 · Cited by 186
Lu, D., Shen, J., Vil, M. D., Zhang, H., Jimenez, X., Bohlen, P., Witte, L., & Zhu, Z. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307742200 · Cited by 183
Trarbach, T., Moehler, M., Heinemann, V, Köhne, C.-H., Przyborek, M., Schulz, C., Sneller, V, Gallant, G., & Kanzler, S. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605507 · Cited by 180
Reichert, J. M. (2016) · mAbs · doi:10.1080/19420862.2015.1125583 · Cited by 175
Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis
Burmester, G. R., Weinblatt, M. E., McInnes, I. B., Porter, D. R., Барбараш, О. Л., Vatutin, M. T., Szombati, I., Esfandiari, E., Sleeman, M. A., Kane, C. D., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202450 · Cited by 172
Camidge, D. R., Herbst, R. S., Gordon, M. S., Eckhardt, S. G., Kurzrock, R., Durbin, B., Ing, J., Tohnya, T. M., Sager, J., Ashkenazi, A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1267 · Cited by 169
Greco, F. A., Bonomi, P., Crawford, J., Kelly, K., Oh, Y., Halpern, W., Lo, L., Gallant, G., & Klein, J. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2007.12.011 · Cited by 168
Salliot, C., Gossec, L., Ruyssen-Witrand, A., Luc, M., Duclos, M., Guignard, S., & Dougados, M. (2006) · Rheumatology · doi:10.1093/rheumatology/kel236 · Cited by 168
Drugs derived from phage display: From candidate identification to clinical practice
Nixon, A. E., Sexton, D. J., & Ladner, R. C. (2014) · mAbs · doi:10.4161/mabs.27240 · Cited by 167
The discovery and development of belimumab: the anti-BLyS–lupus connection
Stohl, W., & Hilbert, D. M. (2012) · Nature Biotechnology · doi:10.1038/nbt.2076 · Cited by 166
Bakker, A. B. H., Marissen, W. E., Kramer, R. A., Papaneri, A. B., Weldon, W. C., Niezgoda, M., Hanlon, C. A., Thijsse, S., Backus, H. H. J., de Kruif, J., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.14.9062-9068.2005 · Cited by 166
Prassler, J., Thiel, S., Pracht, C., Polzer, A., Peters, S., Bauer, M., Nörenberg, S., Stark, Y., Kölln, J., Popp, A., et al. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.08.012 · Cited by 165
Hsu, J. Y., & Wakelee, H. A. (2009) · BioDrugs · doi:10.2165/11317600-000000000-00000 · Cited by 165
Halpern, W., Lappin, P. B., Zanardi, T. A., Cai, W., Corcoran, M. L., Zhong, J., & Baker, K. P. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfj148 · Cited by 158
Reichert, J. M. (2014) · mAbs · doi:10.4161/19420862.2015.988944 · Cited by 156
Behrens, F., Tak, P. P., Østergaard, M., Stoilov, R. M., Wiland, P., Huizinga, T. W. J., Berenfus, V. Y., Vladeva, S., Rech, J., Rubbert‐Roth, A., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204816 · Cited by 152
Cytokine disturbances in systemic lupus erythematosus
Jacob, N., & Stohl, W. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3349 · Cited by 151
A human scFv antibody generation pipeline for proteome research
Hust, M., Meyer, T., Voedisch, B., Rülker, T., Thie, H., El-Ghezal, A., Kirsch, M. I., Schütte, M., Helmsing, S., Meier, D., et al. (2010) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2010.09.945 · Cited by 150
Self-citationSignaling properties of VEGF receptor-1 and -2 homo- and heterodimers
Huang, K., Andersson, C., Roomans, G. M., Ito, N., & Claesson, L. (2001) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(01)00019-x · Cited by 148
Adams, C., Totpal, K., Lawrence, D., Marsters, S., Pitti, R., Yee, S., Ross, S., Deforge, L., Koeppen, H., Sagolla, M., et al. (2008) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402306 · Cited by 148
BAFF Augments Certain Th1-Associated Inflammatory Responses
Sutherland, A. P. R., Ng, L. G., Fletcher, C. A., Shum, B. O. V., Newton, R. A., Grey, S. T., Rolph, M. S., Mackay, F., & Mackay, C. R. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.9.5537 · Cited by 142
Recombinant Antibodies to the Small GTPase Rab6 as Conformation Sensors
Nizak, C., Monier, S., Nery, E. D., Moutel, S., Goud, B., & Perez, F. (2003) · Science · doi:10.1126/science.1083911 · Cited by 142
Lloyd, C., Lowe, D., Edwards, B. M., Welsh, F., Dilks, T., Hardman, C. H., & Vaughan, T. J. (2008) · Protein Engineering Design and Selection · doi:10.1093/protein/gzn058 · Cited by 142
Generation and analysis of the improved human HAL9/10 antibody phage display libraries
Kügler, J., Wilke, S., Meier, D., Tomszak, F., Frenzel, A., Schirrmann, T., Dübel, S., Garritsen, H., Hock, B. M., Toleikis, L., et al. (2015) · BMC Biotechnology · doi:10.1186/s12896-015-0125-0 · Cited by 137
Self-citationProduction of Human Monoclonal and Polyclonal Antibodies in TransChromo Animals
Ishida, I., Tomizuka, K., Yoshida, H., Tahara, T., Takahashi, N., Ohguma, A., Tanaka, S., Umehashi, M., Maeda, H., Nozaki, C., et al. (2002) · Cloning and Stem Cells · doi:10.1089/153623002753632084 · Cited by 136
Lü, D., Jimenez, X., Zhang, H., Böhlen, P., Witte, L., & Zhu, Z. (2001) · International Journal of Cancer · doi:10.1002/ijc.1634 · Cited by 136
Neagoe, P., Lemieux, C., & Sirois, M. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412017200 · Cited by 133
Bakker, A. B. H., Python, C., Kissling, C. J., Pandya, P., Marissen, W. E., Brink, M. F., Lagerwerf, F. M., Worst, S., van Corven, E., Kostense, S., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.08.050 · Cited by 133
A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma
Younes, A., Vose, J. M., Zelenetz, A. D., Smith, M. R., Burris, H. A., Ansell, S. M., Klein, J., Halpern, W., Miceli, R. C., Kumm, E., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605987 · Cited by 132
Preliminary results of early clinical trials with the fully human anti-TNFα monoclonal antibody D2E7
Kempeni, J. (1999) · Annals of the Rheumatic Diseases · doi:10.1136/ard.58.2008.i70 · Cited by 131
Structural Basis for EGF Receptor Inhibition by the Therapeutic Antibody IMC-11F8
Li, S., Kussie, P. H., & Ferguson, K. M. (2008) · Structure · doi:10.1016/j.str.2007.11.009 · Cited by 129
Which are the antibodies to watch in 2013?
Reichert, J. M. (2013) · mAbs · doi:10.4161/mabs.22976 · Cited by 128
Burmester, G. R., Feist, E., Sleeman, M., Wang, B., White, B., & Magrini, F. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146225 · Cited by 127
Cook, A. D., Pobjoy, J., Steidl, S., Dürr, M. C., Braine, E. L., Turner, A. L., Lacey, D. C., & Hamilton, J. A. (2012) · Arthritis Research & Therapy · doi:10.1186/ar4037 · Cited by 126
Stephens, S., Emtage, S., Vetterlein, O. M., Chaplin, L. C., Bebbington, C. R., Nesbitt, A. M., Sopwith, M., Athwal, D., Novak, C., & Bodmer, M. (1995) · PubMed Central · Cited by 124
Phase I Trial and Pharmacokinetic Study of Lexatumumab in Pediatric Patients With Solid Tumors
Merchant, M. S., Geller, J. I., Baird, K., Chou, A. J., Galli, S., Charles, A., Amaoko, M., Rhee, E. H., Price, A. P., Wexler, L. H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.1055 · Cited by 123
Goudsmit, J., Marissen, W. E., Weldon, W. C., Niezgoda, M., Hanlon, C. A., Papaneri, A. B., de Kruif, J., Dietzschold, B., Bakker, A. B. H., & Rupprecht, C. E. (2006) · The Journal of Infectious Diseases · doi:10.1086/500470 · Cited by 121
Diagnosis and treatment of hereditary angioedema with normal C1 inhibitor
Bork, K. (2010) · Allergy Asthma and Clinical Immunology · doi:10.1186/1710-1492-6-15 · Cited by 120
The efficacy of novel B cell biologics as the future of SLE treatment: A review
Kamal, A., & Khamashta, M. A. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.08.020 · Cited by 118
The influence of antibody fragment format on phage display based affinity maturation of IgG
Steinwand, M., Droste, P., Frenzel, A., Hust, M., Dübel, S., & Schirrmann, T. (2013) · mAbs · doi:10.4161/mabs.27227 · Cited by 113
Self-citationRandomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis
Constantinescu, C. S., Asher, A., Fryze, W., Kozubski, W. P., Wagner, F. D., Aram, J., Tănăsescu, R., Korolkiewicz, R. P., Dirnberger‐Hertweck, M., Steidl, S., et al. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000117 · Cited by 113
Granulocyte-macrophage colony stimulating factor exacerbates collagen induced arthritis in mice
Campbell, I. K., Bendele, A. M., Smith, D. A., & Hamilton, J. A. (1997) · Annals of the Rheumatic Diseases · doi:10.1136/ard.56.6.364 · Cited by 110
Biological characterization of human monoclonal antibodies to rabies virus
Dietzschold, B., Gore, M. M., Casali, P., Ueki, Y., Rupprecht, C. E., Notkins, A. L., & Koprowski, H. (1990) · Journal of Virology · doi:10.1128/jvi.64.6.3087-3090.1990 · Cited by 109
Mom, C. H., Verweij, J., Oldenhuis, C. N. A. M., Gietema, J. A., Fox, N. L., Miceli, R. C., Eskens, F. A. L. M., Loos, W. J., de Vries, E. G. E., & Sleijfer, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0996 · Cited by 106
Interaction of antibodies with ErbB receptor extracellular regions
Schmitz, K. R., & Ferguson, K. M. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.10.008 · Cited by 106
Human Antibodies from Transgenic Mice
Lönberg, N., & Huszar, D. (1995) · International Reviews of Immunology · doi:10.3109/08830189509061738 · Cited by 104
Generating recombinant antibodies to the complete human proteome
Dübel, S., Stoevesandt, O., Taussig, M., & Hust, M. (2010) · Trends in biotechnology · doi:10.1016/j.tibtech.2010.05.001 · Cited by 102
Self-citationIn vitro affinity maturation of human GM-CSF antibodies by targeted CDR-diversification
Steidl, S., Ratsch, O., Brocks, B., Dürr, M. C., & Thomassen-Wolf, E. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.07.013 · Cited by 102
Jacob, N., Yang, H., Pricop, L., Liu, Y., Gao, X., Zheng, S. G., Wang, J., Gao, H.-X., Putterman, C., Koss, M. N., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802948 · Cited by 98
Kramer, R. A., Marissen, W. E., Goudsmit, J., Visser, T., der Horst, M. C.-V., Bakker, A. Q., de Jong, M., Jongeneelen, M. A. C., Thijsse, S., Backus, H. H. J., et al. (2005) · European Journal of Immunology · doi:10.1002/eji.200526134 · Cited by 97
From rodent reagents to human therapeutics using antibody guided selection
Osbourn, J. K., Groves, M. A. T., & Vaughan, T. J. (2005) · Methods · doi:10.1016/j.ymeth.2005.01.006 · Cited by 97
Stohl, W., Merrill, J. T., McKay, J. D., LISSE, J. R., Zhong, Z. J., Freimuth, W. W., & Genovese, M. C. (2013) · The Journal of Rheumatology · doi:10.3899/jrheum.120886 · Cited by 97
Reichert, J. M. (2013) · mAbs · doi:10.4161/mabs.27333 · Cited by 96
Kuhn, P., Fühner, V., Unkauf, T., Moreira, G. M. S. G., Frenzel, A., Miethe, S., & Hust, M. (2016) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201600002 · Cited by 90
Self-citationMazumdar, S. (2009) · mAbs · doi:10.4161/mabs.1.6.10195 · Cited by 90
Rise and Fall of an Anti-MUC1 Specific Antibody
Thie, H., Toleikis, L., Li, J., von Wasielewski, R., Bastert, G., Schirrmann, T., Esteves, I. T., Behrens, C. K., Fournès, B., Fournier, N., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015921 · Cited by 89
Self-citationMiao, H., Hu, K., Jimenez, X., Navarro, E. C., Zhang, H., Lu, D., Ludwig, D. L., Balderes, P. J., & Zhu, Z. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.04.119 · Cited by 89
Construction of Human Antibody Gene Libraries and Selection of Antibodies by Phage Display
Schirrmann, T., & Hust, M. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-786-0_11 · Cited by 86
Self-citationBortezomib Combination Therapy in Multiple Myeloma
Kapoor, P., Ramakrishnan, V. G., & Rajkumar, S. V. (2012) · Seminars in Hematology · doi:10.1053/j.seminhematol.2012.04.010 · Cited by 85
Hirsch, F. R., Dziadziuszko, R., Thatcher, N., Mann, H., Watkins, C. L., Parums, D. V., Speake, G., Holloway, B. R., Bunn, P. A., & Franklin, W. A. (2008) · Cancer · doi:10.1002/cncr.23282 · Cited by 80
Schütte, M., Thullier, P., Pelat, T., Wezler, X., Rosenstock, P., Hinz, D., Kirsch, M. I., Hasenberg, M., Frank, R., Schirrmann, T., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006625 · Cited by 80
Self-citationRecombinant therapeutic antibodies
Dübel, S. (2007) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-006-0810-y · Cited by 77
Biondo, M., Nasa, Z., Marshall, A. C. J., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.3.2090 · Cited by 73
Chen, H.-X., Gore‐Langton, R. E., & Cheson, B. D. (2001) · PubMed · Cited by 72
Lehmann, A. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.8.1187 · Cited by 66
Construction of Human Antibody Gene Libraries and Selection of Antibodies by Phage Display
Frenzel, A., Kügler, J., Wilke, S., Schirrmann, T., & Hust, M. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-586-6_12 · Cited by 61
Self-citationAcceptability of switching adalimumab from a prefilled syringe to an autoinjection pen
Borrás‐Blasco, J., Gracia-Pérez, A., Rosique-Robles, J. D., Casterá, M. D.-E., & Abad, F. J. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903530633 · Cited by 60
An improved manufacturing process for Xyntha/ReFacto AF
Kelley, B. D., JANKOWSKI, M., & BOOTH, J. (2009) · Haemophilia · doi:10.1111/j.1365-2516.2009.02160.x · Cited by 59
Muromonab-CD3 (Orthoclone OKT3): the first monoclonal antibody approved for therapeutic use.
Emmons, C., & Hunsicker, L. G. (1987) · PubMed · Cited by 51
Critical Appraisal of Ramucirumab (IMC-1121B) for Cancer Treatment: From Benchside to Clinical Use
Aprile, G., Bonotto, M., Ongaro, E., Pozzo, C., & Giuliani, F. (2013) · Drugs · doi:10.1007/s40265-013-0154-8 · Cited by 50
Discovery of diverse and functional antibodies from large human repertoire antibody libraries
Schwimmer, L. J., Huang, B. C. B., Giang, H. M., Cotter, R. L., Chemla-Vogel, D., Dy, F. V., Tam, E. M., Zhang, F., Toy, P., Bohmann, D. J., et al. (2013) · Journal of Immunological Methods · doi:10.1016/j.jim.2013.02.010 · Cited by 49
[5] Humanization of monoclonal antibodies
Güssow, D., & Seemann, G. H. A. (1991) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/0076-6879(91)03007-4 · Cited by 48
Geng, C., Hou, J., Zhao, Y., Ke, X., Wang, Z., Qiu, L., Xi, H., Wang, F., Wei, N., Liu, Y., et al. (2014) · American Journal of Hematology · doi:10.1002/ajh.23822 · Cited by 48
Rülker, T., Voß, L., Thullier, P., Brien, L. M. O., Pelat, T., Perkins, S. D., Langermann, C., Schirrmann, T., Dübel, S., Marschall, H. ‐., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037242 · Cited by 48
Self-citationNecitumumab: First Global Approval
Garnock-Jones, K. P. (2016) · Drugs · doi:10.1007/s40265-015-0537-0 · Cited by 48
Mazor, Y., Blarcom, T. J. V., Carroll, S., & Georgiou, G. (2010) · FEBS Journal · doi:10.1111/j.1742-4658.2010.07645.x · Cited by 47
Zuraw, B. L., Yasothan, U., & Kirkpatrick, P. N. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3125 · Cited by 45
The therapeutic potential of TRAIL receptor signalling in cancer cells
Yerbes, R., Palacios, C., & López‐Rivas, A. (2011) · Clinical & Translational Oncology · doi:10.1007/s12094-011-0744-4 · Cited by 42
Trott, M., Weiß, S., Antoni, S., Koch, J., von Briesen, H., Hust, M., & Dietrich, U. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097478 · Cited by 39
Self-citationElez, E., Hendlisz, A., Delaunoit, T., Sastre, J., Cervantes, A., Varea, R., Chao, G., Wallin, J., & Tabernero, J. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.480 · Cited by 33 · cited 1×
“The combination therapy was active and toxicity was manageable.(164)”
BackgroundHuman-like antibodies neutralizing Western equine encephalitis virus
Huelseweh, B., Rülker, T., Pelat, T., Langermann, C., Frenzel, A., Schirrmann, T., Dübel, S., Thullier, P., & Hust, M. (2014) · mAbs · doi:10.4161/mabs.28170 · Cited by 33
Self-citationA human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF
Krinner, E.-M., Raum, T., Petsch, S., Bruckmaier, S., SCHUSTER, I., Petersen, L., Cierpka, R., ABEBE, D., Mølhøj, M., & WOLF, A. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2006.03.020 · Cited by 31
Rossant, C. J., Carroll, D. K., Huang, L., Elvin, J. G., Neal, F., Walker, E. H., Benschop, J. J., Kim, E. E., Barry, S. T., & Vaughan, T. J. (2014) · mAbs · doi:10.4161/mabs.34376 · Cited by 31
Krinner, E.-M., Hepp, J., Hoffmann, P., Bruckmaier, S., Petersen, L., Petsch, S., Parr, L., Schuster, I., Mangold, S., Lorenczewski, G., et al. (2006) · Protein Engineering Design and Selection · doi:10.1093/protein/gzl031 · Cited by 30
Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype B
Rasetti‐Escargueil, C., Avril, A., Chahboun, S., Tierney, R., Bak, N., Miethe, S., Mazuet, C., Popoff, M. R., Thullier, P., Hust, M., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1082016 · Cited by 27
Self-citationStructural differences of amyloid-β fibrils revealed by antibodies from phage display
Droste, P., Frenzel, A., Steinwand, M., Pelat, T., Thullier, P., Hust, M., Lashuel, H. A., & Dübel, S. (2015) · BMC Biotechnology · doi:10.1186/s12896-015-0146-8 · Cited by 23
Self-citationZhou, M., Meyer, T., Koch, S., Koch, J., von Briesen, H., Benito, J. M., Soriano, V., Haberl, A., Bickel, M., Dübel, S., et al. (2012) · European Journal of Immunology · doi:10.1002/eji.201242974 · Cited by 18
Self-citationConstruction and characterization of functional anti-epiregulin humanized monoclonal antibodies
Lee, Y.-H., Iijima, M., Kado, Y., Mizohata, E., Inoue, T., Sugiyama, A., Doi, H., Shibasaki, Y., & Kodama, T. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.11.014 · Cited by 17
Engesæter, B. Ø., Engebraaten, O., Flørenes, V. A., & Mælandsmo, G. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045492 · Cited by 16
New series of vectors for phage display and prokaryotic expression of proteins.
Paschke, M., Zahn, G., Warsinke, A., & Höhne, W. E. (2001) · PubMed · Cited by 14
Cited by
Therapeutic Peptides: Current Applications and Future Directions
Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., & Fu, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00904-4 · Cited by 2,131
Development of therapeutic antibodies for the treatment of diseases
Lu, R.-M., Hwang, Y.-C., Liu, I.-J., Lee, C.-C., Tsai, H.-Z., Li, H.-J., & Wu, H.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0592-z · Cited by 2,085
The Current State of Peptide Drug Discovery: Back to the Future?
Henninot, A., Collins, J. C., & Nuss, J. M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00318 · Cited by 1,113
Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics
Bannas, P., Hambach, J., & Koch-Nolte, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01603 · Cited by 572
“Daratumumab (anti-CD38), for example, was generated from immunized human Ig-transgenic mice, necitumumab (antiEGFR) was selected from a fully synthetic Fab display library (44).”
MethodKaplon, H., & Reichert, J. M. (2019) · mAbs · doi:10.1080/19420862.2018.1556465 · Cited by 434
Metadata
- Authors
- Frenzel, A., Schirrmann, T., & Hust, M.
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2016-08-15
- Volume
- 8
- Issue
- 7
- Pages
- 1177-1194
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- OpenAlex
- W2474760928
- Cited by
- 346
- References
- 182
- FWCI
- 27.86
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.